No Data
AIM Announces Paul Goepfert, MD, as the Principal Investigator for the Planned Clinical Study of Ampligen and FluMist as a Vaccine for Avian Influenza
Express News | AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance
Express News | AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director
Press Release: AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director
AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
AIM ImmunoTech and Erasmus MC Announce Progress on Phase 2 Trial for Ampligen and Imfinzi in Late-Stage Pancreatic Cancer
what do you think can go up to
